Welcome to the NHP Functional Genomics Core for AIDS Vaccine Research and Development 

The NHP Functional Genomics Core

is housed in the Gale laboratory at the

The mission of the NHP Functional Genomics Core is to ensure standardization and comparability of functional genomics services and assays conducted for the Simian Vaccine Evaluation Unit (SVEU)  and other DAIDS-supported preclinical NHP studies.

We apply high throughput functional genomics approaches in these NHP studies to more effectively evaluate vaccine-induced adaptive and innate immune responses and vaccine efficacy in challenge/protection studies and identify host responses that predict vaccine efficacy.

Nonhuman primate (NHP) models present an opportunity to test a variety of candidate AIDS vaccines, optimizing their ability to elicit immune responses and testing their ability to prevent infection or to control virus replication after virus challenge.

The NHP Functional Genomics Core is supported by the Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH).

The mission of DAIDS is to ensure an end to the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic by supporting research that can lead to the development of therapies, vaccines, and prevention strategies. 

News and Events

Functional genomics lab to predict potential AIDS vaccines efficacy and find protection markers

Publications of Interest

Deep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activation

Mathematical models of viral latency

Next-Generation Sequencing of Small RNAs from HIV-Infected Cells Identifies Phased microRNA Expression Patterns and Candidate Novel microRNAs Differentially Expressed upon Infection

Dynamics of innate immunity are key to chronic immune activation in AIDS

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.